1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Lorus Therapeutics Inc. - Product Pipeline Review - 2013

Lorus Therapeutics Inc. - Product Pipeline Review - 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 42 pages

Lorus Therapeutics Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Lorus Therapeutics Inc. - Product Pipeline Review - 2013” provides data on the Lorus Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Lorus Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Lorus Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Lorus Therapeutics Inc. - Brief Lorus Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lorus Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lorus Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lorus Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Lorus Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lorus Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lorus Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lorus Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lorus Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

Lorus Therapeutics Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Lorus Therapeutics Inc. Snapshot 5
Lorus Therapeutics Inc. Overview 5
Key Information 5
Key Facts 5
Lorus Therapeutics Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Lorus Therapeutics Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Lorus Therapeutics Inc. - Pipeline Products Glance 11
Lorus Therapeutics Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Lorus Therapeutics Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Lorus Therapeutics Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Lorus Therapeutics Inc. - Drug Profiles 16
Drug For Solid Tumors 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
IL-17E 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
LOR-1284 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
LOR-2040 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
LOR-220 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
LOR-253 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
LOR-264 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
LOR-500 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
LOR-739 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
LOR-742 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Pancratistatin Derivatives 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Virulizin 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Lorus Therapeutics Inc. - Pipeline Analysis 28
Lorus Therapeutics Inc. - Pipeline Products by Therapeutic Class 28
Lorus Therapeutics Inc. - Pipeline Products By Target 29
Lorus Therapeutics Inc. - Pipeline Products by Route of Administration 30
Lorus Therapeutics Inc. - Pipeline Products By Mechanism of Action 31
Lorus Therapeutics Inc. - Recent Pipeline Updates 33
Lorus Therapeutics Inc. - Dormant Projects 38
Lorus Therapeutics Inc. - Company Statement 39
Lorus Therapeutics Inc. - Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42



List of Tables

Lorus Therapeutics Inc., Key Information 5
Lorus Therapeutics Inc., Key Facts 5
Lorus Therapeutics Inc. - Pipeline by Indication, 2013 8
Lorus Therapeutics Inc. - Pipeline by Stage of Development, 2013 9
Lorus Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 10
Lorus Therapeutics Inc. - Phase III, 2013 11
Lorus Therapeutics Inc. - Phase II, 2013 12
Lorus Therapeutics Inc. - Phase I, 2013 13
Lorus Therapeutics Inc. - Preclinical, 2013 14
Lorus Therapeutics Inc. - Discovery, 2013 15
Lorus Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 28
Lorus Therapeutics Inc. - Pipeline By Target, 2013 29
Lorus Therapeutics Inc. - Pipeline By Route of Administration, 2013 30
Lorus Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 32
Lorus Therapeutics Inc. - Recent Pipeline Updates, 2013 33
Lorus Therapeutics Inc. - Dormant Developmental Projects,2013 38
Lorus Therapeutics Inc., Subsidiaries 40



List of Figures

Lorus Therapeutics Inc. - Pipeline by Indication, 2013 7
Lorus Therapeutics Inc. - Pipeline by Stage of Development, 2013 9
Lorus Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 10
Lorus Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 28
Lorus Therapeutics Inc. - Pipeline By Route of Administration, 2013 30
Lorus Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.